Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF)

NCT05328752 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Failure With Reduced Ejection Fraction (HFrEF)
or Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)

Interventions

DRUG: XXB750
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals